Pharmacy

Your Article Summary

See Latest Articles

A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US
Current Medical Research and Opinion, 06/25/09

Charles MS et al. - Under a range of assumptions and study limitations around cohorts, clinical effects, and treatment patterns, this long-term analysis showed that pioglitazone plus metformin, when compared to rosiglitazone plus metformin, was a dominant treatment strategy within the US payer setting. Results were driven by the combination of modest differences in QALYs and modest savings in total complication costs over 35 years.

Today in Other Drugs...keeping you current

Receive free subspecialty "5-minute updates" via email

Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09

Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09

Biphasic effects of hormone treatment on risk of cardiovascular disease
Sexuality, Reproduction & Menopause, 10/20/09

See All of Other Drugs

Today in Pharmacoeconomics...keeping you current

Receive free subspecialty "5-minute updates" via email

Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09

Use and cost of branded and generic drugs in patients with coronary heart disease-results from a prospective survey of 1008 patients in two London hospitals
QJM: An International Journal of Medicine, 10/16/09

Clinical and Economic Comparison of Frovatriptan Versus other Oral Triptans in the Treatment of Acute Migraine in the Real-World Setting
Clinical Drug Investigation, 10/15/09

See All of Pharmacoeconomics